NOS2 and neoplasm: Evidence supports that inhibiting the activity of ARG and iNOS using specific inhibitors (N-monomethyl-L-arginine for iNOS and N-hydroxy-L-arginine for ARG) allows tumour-infiltrating lymphocytes to recover their responsiveness to tumour antigens [40].